Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.

Subjects

Subjects :

Adenocarcinoma, Papillary genetics
Adenocarcinoma, Papillary pathology
Aged
Carcinoma, Signet Ring Cell drug therapy
Carcinoma, Signet Ring Cell genetics
Carcinoma, Signet Ring Cell pathology
DNA Mutational Analysis
Erlotinib Hydrochloride
Exons
Female
Humans
Immunohistochemistry
Mutation
Polymerase Chain Reaction
Thyroid Neoplasms genetics
Thyroid Neoplasms pathology
Adenocarcinoma, Papillary drug therapy
Antineoplastic Agents therapeutic use
Epidermal Growth Factor genetics
Quinazolines therapeutic use
Thyroid Neoplasms drug therapy

Details

Language :

English

ISSN :

1527-7755

Volume :

29

Issue :

16

Database :

MEDLINE

Journal :

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

21422425

Full Text :

https://doi.org/10.1200/JCO.2010.34.0216